- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Insmed Inc(INSM)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for INSM
11/13/2026: INSM (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Insmed Inc is a commercial-stage biopharmaceutical stock specializing in therapies for rare respiratory and inflammatory diseases. Its primary operational strength lies in the successful commercialization of ARIKAYCE and a promising late-stage pipeline anchored by brensocatib. The core investment story centers on rapid top-line revenue expansion and upcoming label extensions addressing major underserved patient populations. Key risks involve persistent net losses, execution demands, and regulatory uncertainty inherent in biotechnology development. The stock best suits growth-oriented investors willing to monitor clinical readouts and commercial scale-up progress.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Insmed delivers rapid top-line revenue expansion and operates in high-growth rare disease therapeutic markets. |
| Momentum investor | Strong fit while signal remains positive | The stock experiences significant price swings and volume reactions driven by clinical catalysts and revenue beats. |
| Value investor | Weak fit | The company currently operates at a net loss and trades at high valuation multiples without traditional earnings or P/E support. |
| Dividend investor | Weak fit | Insmed pays no dividends, reinvesting all available capital into clinical pipeline development and commercial scale. |
| Low-risk investor | Weak fit | Clinical trial binary events, regulatory uncertainty, and high stock volatility present substantial risk profiles. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotechnology stocks frequently react sharply to clinical trial updates, regulatory decisions, and earnings reports. |
| Valuation risk | Medium / high | High market expectations and growth multiples leave the stock vulnerable if revenue growth decelerates. |
| Competition risk (specialized rare disease biopharma competition) | Medium | Competitors developing alternative therapies can erode market share and pricing power in orphan indications. |
| Business quality | Medium | Proprietary drug delivery tech and approved products demonstrate operational viability, though net profitability is nascent. |
| Dividend income | Low / none | No cash dividends are distributed to shareholders. |
| Execution risk | High | Successful global commercial rollouts and clinical trial execution are critical to validating the company's valuation. |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 26.58B USD | Price to earnings Ratio - | 1Y Target Price 194.18 |
Price to earnings Ratio - | 1Y Target Price 194.18 | ||
Volume (30-day avg) 3.6M shares | Beta 0.81 | 52 Weeks Range 90.39 - 212.75 | Updated Date 11/15/2026 |
52 Weeks Range 90.39 - 212.75 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.81 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Steep Decline
The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 40.5% | Avg. Invested days 33 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Commercial Therapeutics Sales | Global sales of approved specialty medications, primarily ARIKAYCE for refractory NTM lung disease. | The vast majority of revenue comes from sales of specialized prescription drugs to treat rare lung conditions. |
| Geographic Markets (North America, Europe, International) | Commercial distribution and licensing agreements across the United States, Europe, Japan, and international markets. | Revenue is diversified across major developed pharmaceutical markets with localized distribution partnerships. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE 107.53 | Enterprise Value 26.02B | Price to Sales(TTM) 17.49 |
Enterprise Value 26.02B | Price to Sales(TTM) 17.49 | ||
Enterprise Value to Revenue 17.12 | Enterprise Value to EBITDA -6.05 | Shares Outstanding 219.38M | Shares Floating 217.93M |
Shares Outstanding 219.38M | Shares Floating 217.93M | ||
Percent Insiders 1.01 | Percent Institutions 104.54 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

